Skip to content

Tick-Borne Encephalitis Virus IgG Control Serum BC112G

$94.00

Summary

  • Virion/Serion Diagnostic Kit Control for research use (RUO)
  • Tick-Borne Encephalitis Virus IgG Control Serum
  • Applications: ELISA
  • IgG control serum
  • Ready-to-use; pre-diluted for SERION ELISA classic and SERION ELISA antigen assays
  • 3 mL
Weight1 lbs
Dimensions9 × 5 × 2 in
target

Tick-Borne Encephalitis Virus reactive IgG

species reactivity

Tick-Borne Encephalitis Virus

applications

ELISA

assay type

Indirect & quantitative

available size

3 mL

Available product – Tick-Borne Encephalitis Virus IgG Control Serum BC112G

kit
Research area
Infectious Disease
Storage
Store at 2-8°C.
Associated products
FSME/TBE (Tick-Borne Encephalitis) Virus (Premium) Antigen (BA112VS)
FSME/TBE (Tick-Borne Encephalitis) Virus Antigen (BA112VSL)
Tick-Borne Encephalitis Virus IgG Control Serum (BC112G)
Tick-Borne Encephalitis Virus IgM Control Serum (BC112M)
Tick-Borne Encephalitis Virus IgG ELISA Kit (ESR112G)
Tick-Borne Encephalitis Virus IgM ELISA Kit (ESR112M)
target relevance
Organism
Tick-Borne Encephalitis Virus (FSME/TBE Virus)
Structure and strains
Tick-borne encephalitis virus (TBEV) is a positive-strand RNA virus associated with tick-borne encephalitis in the genus Flavivirus.
Disease
TBE Viruses can be transmitted to humans by infected ticks and may cause the so called tick-borne encephalitis (TBE). They belong to the human pathogenic species among the flaviviruses. Of particular note is the highly immunogenic envelope protein E, embedded in the surface of the virus. TBE Viruses are distributed throughout Europe and Asia. Depending upon their distribution, the three TBE Virus variants are referred to as the Central European, Siberian or Far Eastern subtype.

The majority of TBE Virus infections remain clinically asymptomatic. In 30% of cases, a biphasic course of disease starts with the onset of flu-like symptoms following an incubation period of 7 to 14 days. After a fever-free interval of one week, 10% of patients go on to develop encephalitis or meningoencephalitis, occasionally with long-lasting neurological symptoms. The majority of patients recover fully, even when the infection takes a severe course. However, there is a morbidity rate of around 1% for patients with CNS involvement. A naturally aquired infection usually leads to life-long immunity. In contrast, immunization results in limited immune protection and should be refreshed at regular intervals.
Detection and diagnosis
Cultivation of the TBE Virus is complex, time consuming and requires special safety precautions. Direct pathogen detection by RT-PCR is possible at the onset of disease, however, a negative result does not rule out a TBE Virus infection. As a consequence, the determination of pathogen-specific antibodies by ELISA is recommended for laboratory confirmation of TBE Virus infections. The combined demonstration of IgG and IgM antibodies directed against TBE Virus, a significant increase in antibody activity by the analysis of serum pairs or the detection of intrathecally synthesized IgG or IgM antibodies serve to confirm an infection.

Data

Publications

Published literature highly relevant to the biological target of this product and referencing this antibody or clone are retrieved from PubMed database provided by The United States National Library of Medicine at the National Institutes of Health.




pmidtitleauthorscitation

Protocols

relevant to this product
BC112G protocol

Documents

#
No results found

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.